PAP
LPCN icon

Persistent Asset Partners’s Lipocine LPCN Stock Holding History

Persistent Asset Partners’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Sell
13,442
-57,134
-81% -$498K 0.04% 234
2025
Q4 		$567K Buy
+70,576
New +$237K 0.25% 114

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Persistent Asset Partners's LPCN Position: Q1 2026 in Review

Persistent Asset Partners reduced its Lipocine (LPCN) stake by 81% in Q1 2026, selling an estimated $498K and leaving 13,442 shares worth $107K. The position accounts for 0.04% of the portfolio, ranked #234.

Persistent Asset Partners first reported a position in LPCN in Q4 2025 and has held it in 2 quarters since. The position peaked at $567K in Q4 2025. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Persistent Asset Partners held 13,442 shares of Lipocine worth $107K as of Q1 2026.
  • Persistent Asset Partners sold 57,134 Lipocine shares in Q1 2026, an estimated $498K.
  • Lipocine made up 0.04% of Persistent Asset Partners's portfolio in Q1 2026, its #234 holding.
  • Persistent Asset Partners first reported a position in Lipocine in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Lipocine position peaked at $567K in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.